Fig. 4.

PAKib suppressed PC growth in vivo and enhanced the inhibitory effect of gemcitabine on PC. KPCPAK1WT833 cells (50,000 cell/100 μl DMEM plus 5% FBS) were subcutaneously injected into the back of the right hind leg of a mouse. The mice were treated with PAKib (40 mg/Kg) by a subcutaneous injection (s.i.) every second day when tumour volume reached above 70 mm³ in set one (A-D) experiment where the initial average tumour volumes were 77.51±12.27 mm³ and 70.77±11.41 mm³ for control (CT, n=4) and PAKib (n=4) respectively (B). In set two experiment (E-H), when tumour volume reached 100 mm³, mice were treated with gemcitabine (Gem, 25 mg/Kg) alone every fourth day by intraperitoneal injection (i.p.) or Gem plus PAKic (40 mg/Kg, s.i. every second day). For set two experiment, the initial tumour volumes were 106.34+12.48 mm³, 113.12+13.82 mm³, and 114.53+3.94 mm³ for CT (n=5), Gem alone (n=4) and Gem plus PAKib (n=4) respectively (F). *, p<0.05 compared to CT; #, p<0.05 compared to Gem plus PAKib.